MORPHINE AND NSAIDs FAVORED BY AHCPR PANEL AS ORAL CANCER PAIN THERAPIES BECAUSE OF LOW COST, EASE OF ADMINISTRATION; AGGRESSIVE TREATMENT URGED
Executive Summary
Nonsteroidal anti-inflammatory drags, morphine and other opiates should be used as initial therapy for cancer pain because they are the "simplest, least invasive and inexpensive drags" for that use, declared Ada Jacox, co-chair of the HHS Agency for Health Care Policy & Research panel on cancer pain at a March 2 introductory press conference for the new clinical practice guidelines.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth